BioOrigin Co., Ltd. is a medical device company established in July 2009. It primarily develops and manufactures medical supplies based on biomaterials, such as synthetic bone graft substitutes, and is headquartered in Damyang-gun, Jeollanam-do. The representative is Heo Sung-kyu.

"BioOrigin Co., Ltd. is a company that has built proven technology and trust in the medical field, centered around synthetic bone graft substitutes. It focuses on creating technology that doctors actually choose and is growing based on its proprietary Biomaterial technology, supported by SCI-level papers and patents. By creating practical solutions that consider the entire process from development, approval, production, to actual clinical settings, it aims to provide confidence to medical professionals and better recovery to patients."

Business Areas

• Development and Manufacturing of Biomaterial-Based Medical Devices: BioOrigin develops and manufactures medical devices based on biomaterials, including synthetic bone graft substitutes. It particularly handles bone graft substitutes as its main products in the field of human tissue/graft materials.
• Sales of Medical Devices and Medical Supplies: Engages in the business of selling manufactured medical devices and medical supplies in domestic and international markets. Contributes to the production of high-value-added products through securing the domestic market and strengthening export competitiveness.
• R&D and Technology Development: Actively participates in technology development by undertaking national R&D related to 3D printing, custom implants, and vibrational friction fusion. Strengthens its proprietary technological capabilities through SCI-level papers and patents.

Products

• U-BONE (Granule Type): A purely domestic synthetic bone product developed for general bone replacement purposes. It is based on high-purity β-TCP, enhancing absorbability and strength, with a low risk of viral contamination and a low possibility of inducing immune responses.
• U-Bone Injectable: An injectable synthetic bone graft substitute developed for convenient application in medical settings. It is a product that received MFDS product approval in May 2024.
• LEOPARD X: A curable synthetic bone graft substitute, approved by the MFDS in January 2026. It is introduced as a product embodying BioOrigin's technological philosophy.

Special Notes

• Innovative Biomaterial Technology: Based on proprietary technology with SCI-level papers and patents in the field of synthetic bone graft substitutes. Possesses innovative technologies such as product development using high-purity β-TCP and application of 3D printing technology.
• Medical Device Quality and Regulatory Competence: As a Class 4 medical device company, it has a strict quality management system, including renewing GMP certification and obtaining ISO 13485 certification. Many products have received MFDS product approval.
• Field-Oriented Product Development: Focuses on creating 'technology that doctors actually choose' rather than 'technology that can be made,' providing practical solutions that consider the entire process from development to actual clinical settings.

Recruitment Information

• Main Hiring Positions: Primarily hires for production and production management positions, overseeing the entire production of Class 4 medical devices, and managing process flow and GMP documentation.
• Benefits: Lunch meal support is provided.

💡 A Word from JobPloy
BioOrigin Co., Ltd. is a company that manufactures medical supplies, especially synthetic bone graft substitutes, a field where precise production and quality control are crucial. It primarily hires for production and production management roles, requiring an understanding of the medical device manufacturing environment and meticulousness. Benefits include meal support, offering an opportunity to develop expertise in a stable working environment.